Details of Drug-Drug Interaction
| Drug General Information (ID: DDIHQXB0FV) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Interferon alfa-n1 | Drug Info | Pegfilgrastim | Drug Info | |||||
| Drug Type | Interferons | Small molecule | |||||||
| Therapeutic Class | Antiviral Agents | Immunomodulatory Agents | |||||||
| Mechanism of Interferon alfa-n1-Pegfilgrastim Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Interferon alfa-n1 | Pegfilgrastim | |||||||
| Mechanism | Reduce therapeutic efficacy of hematopoietic growth factors | Hematopoietic growth factors | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA. | ||||||||||||||||||
| 2 | Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA. | ||||||||||||||||||